CSIMarket
 
Dyne Therapeutics Inc   (DYN)
Other Ticker:  
 
 
Price: $26.2800 $-1.71 -6.109%
Day's High: $28.265 Week Perf: -3.03 %
Day's Low: $ 26.16 30 Day Perf: 11.36 %
Volume (M): 2,325 52 Wk High: $ 30.27
Volume (M$): $ 61,098 52 Wk Avg: $13.13
Open: $27.57 52 Wk Low: $6.40



 Market Capitalization (Millions $) 1,598
 Shares Outstanding (Millions) 61
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -208
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Dyne Therapeutics Inc


   Company Address: 1560 Trapelo Road Waltham 2451 MA
   Company Phone Number: 786-8230   Stock Exchange / Ticker: NASDAQ DYN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Dyne Therapeutics Showcases Impressive Initial Clinical Data from ACHIEVE and DELIVER Trials at Muscular Dystrophy Association Conference

Published Wed, Feb 14 2024 9:15 PM UTC

Dyne Therapeutics, a leading biotechnology company dedicated to developing novel therapies for patients with muscle diseases, recently announced the presentation of exciting initial clinical data from its ACHIEVE and DELIVER trials. These groundbreaking trials focus on Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), demonstrating promising results in v...

Financing Agreement

Fueling Innovation and Growth: Dyne Therapeutics Shores Up Funds with Successful Public Offering and Eyes Industry Progression

Published Thu, Jan 11 2024 9:05 PM UTC



Dyne Therapeutics, a clinical-stage muscle disease company specializing in genetic-driven disease therapeutics, has recently concluded its underwritten public offering of common stock, resulting in significant proceeds. The offering, coupled with the company's financial performance in the previous year, has consequential implications for Dyne's growth trajectory an...

Stock Market Announcement

Dyne Therapeutics' Successful Public Offering Sparks Excitement Among Shareholders, Reinforcing Confidence in the Company's Growth Potential

Published Fri, Jan 5 2024 3:47 AM UTC

Dyne Therapeutics Announces Pricing of Public Offering, Significantly Boosting Shareholder Confidence
WALTHAM, Mass., Jan. 04, 2024 ?? Dyne Therapeutics, Inc. (Nasdaq:DYN), a leading muscle disease company, made a groundbreaking announcement today regarding the pricing of its underwritten public offering. The company intends to offer 17,150,000 shares of common stock at ...

Financing Agreement

Dyne Therapeutics Announces Underwritten Public Offering of $175 Million in Common Stock to Advance Life-Transforming Therapeutics for Genetically Driven Diseases

Published Wed, Jan 3 2024 9:25 PM UTC

Dyne Therapeutics Plans Underwritten Public Offering of $175 Million in Common Stock
Dyne Therapeutics, a clinical-stage muscle disease company specializing in therapeutics for genetically driven diseases, has recently announced the commencement of an underwritten public offering. The company aims to raise $175 million by selling shares of its common stock. In addition, ...

Clinical Study

FORCE Platform Demonstrates Potential in Battle Against Rare Muscle Diseases: Findings from Dyne Therapeutics' ACHIEVE and DELIVER Trials

Published Wed, Jan 3 2024 11:30 AM UTC

In an encouraging stride forward, Dyne Therapeutics has recently announced preliminary positive clinical data stemming from their ACHIEVE and DELIVER trials. These trials represent prospective shaping of the future, with the rehabilitation of therapy for individuals suffering from Myotonic Dystrophy Type 1 (DM1) and Duchene's Muscular Dystrophy (DMD) ?? both debilitating rar...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com